Chronic kidney disease

Audience: Patients and providers
Status: Clinical guide · patient + provider
Last updated: 2026-03-09

1. Clinical overview

Chronic kidney disease is persistent structural or functional kidney impairment that raises cardiovascular risk, medication-safety risk, and progression risk well before kidney failure develops.

2. Common causes and risk factors

Progressive loss of kidney function from diabetes, hypertension, glomerular or structural disease.
Albuminuria and declining eGFR indicate elevated cardio-renal risk.

3. Typical symptoms

Often silent early; late findings include fatigue, edema, pruritus, appetite change.

4. Diagnosis and evaluation

Confirm diagnosis with guideline-based history, exam, and indicated testing.
Screen for severity, complications, and high-risk comorbid conditions.
Identify social or access barriers that could affect treatment success.

5. Treatment (non-pharmacologic)

Blood pressure, glycemic, and lifestyle optimization.
Nephrotoxin minimization and vaccination.
Nutrition counseling (sodium/protein/phosphorus individualized).

6. Treatment (pharmacologic)

ACE inhibitors or ARBs such as lisinopril, losartan, or irbesartan are foundational in albuminuric disease when tolerated.
SGLT2 inhibitors such as empagliflozin or dapagliflozin provide kidney and cardiovascular protection in eligible patients.
Additional therapy may include finerenone for persistent albuminuria and bicarbonate, iron, ESA, or phosphate-binder pathways depending on stage-specific complications.

7. Monitoring and follow-up

eGFR, UACR, potassium, bicarbonate, anemia/mineral bone markers by stage.

8. Practical counseling points

Give patients a clear “what to do today / when to call / when to seek urgent care” plan.
Use teach-back to confirm understanding of treatment goals and medication instructions.
Simplify regimens when possible to improve adherence and outcomes.

9. Red flags and escalation

Escalate care urgently for severe or rapidly worsening symptoms.
Reassess diagnosis if expected response does not occur within the anticipated timeline.

10. Guideline references

KDIGO CKD and diabetes-in-CKD guidelines.
National Kidney Foundation resources.
ACC/AHA prevention guidance for CKD risk reduction.

Note: Educational guide only; not a substitute for individualized medical care.